诱导结束时PML-RARA转录本水平与非高危急性早幼粒细胞白血病预后相关
Despite the high cure probability for acute promyelocytic leukaemia (APL), a minority of patients will relapse and the risk factors for relapse are unclear.…
核心结论
- 长期随访证实ATRA联合口服砷剂一线治疗非高危APL治愈率高,诱导结束时PML-RARA转录本水平与复发相关。
研究设计与样本
- 单中心回顾性队列研究,纳入2014年2月至2018年12月北京大学血液病研究所212例非高危APL患者。
- 176例(83%)接受口服砷剂(复方黄黛片)联合ATRA,36例(17%)接受三氧化二砷联合ATRA,203例可评估复发。
临床怎么用
- 对非高危APL患者,一线可采用ATRA联合口服砷剂方案,治愈率高。
局限性
- 单中心回顾性研究,样本量有限,结论需多中心前瞻性验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Despite the high cure probability for acute promyelocytic leukaemia (APL), a minority of patients will relapse and the risk factors for relapse are unclear. We retrospectively analysed 212 patients who were diagnosed with non-high-risk APL and received all-trans retinoic acid (ATRA) plus arsenic as front-line therapy at Peking University Institute of Hematology from February 2014 to December 2018. A total of 176 patients (83%) received oral arsenic (realgar-indigo naturalis formula) plus ATRA, 36 patients (17%) received arsenic trioxide plus ATRA and 203 patients were evaluable for relapse. After a median (range) follow-up of 53·6 (24·3-85·4) months, two patients had molecular relapse and eight had haematological relapse. A promyelocytic leukaemia/retinoic acid receptor alpha (PML-RARA) transcript level of ≥6·5% at the end of induction therapy was associated with relapse (P = 0·031). The 5-year cumulative incidence of relapse, event-free survival and overall survival were 5·5%, 92·3% and 96·3% respectively. In conclusion, the present long-term follow-up study further confirmed the high cure probability of ATRA plus oral arsenic as front-line therapy for non-high-risk APL and showed that the PML-RARA transcript level at the end of induction therapy was associated with relapse.
引用
- Tang FF, Lu SY, Zhao XS, et al. PML-RARA transcript levels at the end of induction therapy are associated with prognosis in non-high-risk acute promyelocytic leukaemia with all-trans retinoic acid plus arsenic in front-line therapy: long-term follow-up of a single-centre cohort study. Br J Haematol. 2021. PMID: 34405393. doi:10.1111/bjh.17752
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。